Histopathological Characteristics: Clinical Course of Breast Cancer Subtypes Depending on the ER(+) (−)/PR(+) (−) Receptor Status [chapter]

Nilufer Bulut
2017 Breast Cancer - From Biology to Medicine  
Breast cancer patients were divided into separate groups, which were the estrogen receptor (ER)+/progesterone receptor (PR)+ HER2−, the ER or PR+ HER2−, the ER+/ PR+ HER2+, the ER or PR+ HER2+, the ER−/PR− HER2−, and the ER−/PR− HER2+ groups. Patients with the ER/PR(+)/HER2− subtype breast cancers show better clinical prognosis compared to the hormone-negative, triple-negative (TN), and HER2+ subtypes. TN, HER2+ tumors in postmenopausal women were of higher grade, showing lymph node and
more » ... ph node and lymphovascular invasion with poor prognosis in all case series. However, the ER+/PR−/HER2+ subgroup had the lowest survival rates in 2and 5-year follow-ups. Comparison between the ER+PR+HER2+ and ER+PR−HER2− subgroups showed that HER2− status is an indicator of improved prognosis in longterm follow-up. Single hormone receptor (HR)(+) status, particularly HER2(−) cases, was in between the favorable and poor survival subgroups. The ER−, PR−, and HER2+ properties were found to be risk factors for frequent recurrences. In this chapter, breast cancer subtypes are compared with each other. Results from different studies highlight the importance of ER/PR/HER2 receptor variations in the choice of treatment and prognosis of breast cancer.
doi:10.5772/66176 fatcat:4uelmexzwnb6ndgkdoqawdpiw4